PubMed HealthSearch

PubMed · 3120566

Nitrate tolerance.

Abstract

The organic nitrates are the most widely used agents in the management of patients with angina pectoris. When initially administered by the oral route, the nitrates produce profound changes in systemic hemodynamics and significant and prolonged improvement in exercise duration. It has been shown that during short periods of regular oral nitrate administration, the hemodynamic, antiischemic and antianginal effects of the nitrates are greatly reduced. Thus, when initially administered, oral isosorbide dinitrate prolongs exercise duration for a period of several hours, but during sustained 4-times-daily therapy, exercise tolerance is improved for only 2 hours after administration. Studies with transdermal preparations of isosorbide dinitrate and nitroglycerin also show improvement during short-term administration for up to 8 hours, but after several days of once-daily therapy, the effects of these agents are similar to placebo. It is apparent that nitrate tolerance is a clinically relevant problem. Although tolerance develops rapidly during nitrate therapy, it is reversed promptly during nitrate-free periods. Oral nitrates maintain their antianginal effects when given 2 or 3 times daily with provision of a nitrate-free period. Studies are currently underway to investigate the effects of intermittent administration schedules with transdermal nitrate preparations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J O Parker. 1987-11-16. Nitrate tolerance.. https://doi.org/10.1016/0002-9149(87)90551-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Prospects for controlled-delivery systems.

Americans seem to view medical progress as a citizen's entitlement. They expect, and researchers expect to seek, cures for acquired immunodeficiency syndrome (AIDS), Alzheimer's disease, cancer, and other deadly or incapacitating diseases. Both the public and researchers also seem undaunted by the cost. CDS technologies and biotechnology drugs are making this expectation possible. Still, CDSs may not dispel public resentment over the high cost--and profit--of discovering otherwise welcomed new healing molecules. As noted by 1988 Nobel laureate in medicine, Sir James Black: "I think both the press and industry have failed to communicate to the public that behind every little pill is a vast amount of high technology...." With increasing use of and satisfaction from CDSs, more of these mechanisms, covering a broadening spectrum of uses, will be marketed. Because these products are taken less often, patient compliance is expected to increase. As more CDSs are introduced, dispensing frequency will decline and the complexity of prescription drugs will increase. Pharmacists can take advantage of this trend by expanding their activities in the management their patients' medication use.

Dosage Forms